Recent collaborations and discoveries are advancing cancer treatments. Mount Sinai’s OCCAM Immune and Cancer Research Institute joined forces to enhance immunotherapy outcomes through integrated immune monitoring in clinical trials. Multiple studies reveal promising developments: a novel anti-HER2 monoclonal antibody targeting tumor-specific epitopes, multifunctional nanoparticles enabling bimodal phototherapy for bladder cancer, and innovative enzyme-targeting strategies for neuroblastoma differentiation therapy. These efforts underscore progress toward personalized and targeted oncology modalities.